Trial Outcomes & Findings for A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder (NCT NCT01193153)

NCT ID: NCT01193153

Last Updated: 2015-01-05

Results Overview

Relapse was defined as first occurrence of any 1 of following:psychiatric hospitalization due to worsening symptoms; any intervention employed to avert imminent hospitalization due to worsening symptoms or need for additional antipsychotic,antidepressants/mood stabilizing medication; deliberate self-injury,suicidal/homicidal ideation that is clinically significant as determined by investigator,or violent behavior resulting in clinically significant injury to another person or property damage; worsening of any 1 or more of 8 selected positive and negative syndrome scale(PANSS) items to a score of greater than or equal to (\>= 6) after randomization(if the score for the corresponding item was less than or equal to \[\<=\] 4 at randomization); worsening of certain other measures in specific ways at 2 consecutive visits. Relapse by subgroup of participants on monotherapy,adjunctive therapy to antidepressants/mood stabilizers,participants with psychotic symptoms/mood symptoms was examined.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

667 participants

Primary outcome timeframe

Day 1 up to Month 15 of double blind relapse prevention period

Results posted on

2015-01-05

Participant Flow

Participants without previous exposure to paliperidone extended-release (ER) (Invega), or risperidone, received paliperidone ER 6 milligram (mg)/day for 4 to 6 days (during Screening) to test oral tolerability. Only participants, who had ability to tolerate the drug, as judged by treating physician, were eligible for enrollment in the study.

Participant milestones

Participant milestones
Measure
Paliperidone Palmitate
Open Label (OL) Lead-in (13 weeks): 234 milligram (mg) injection on Day 1, 156 mg on Day 8, flexible dose between 78-234 mg on Days 36, 64, and 92. Participants who met criteria: Positive and Negative Syndrome Scale (PANSS) total score less than or equal to (\<=) 70, and Young Mania Rating Scale \[YMRS\] and Hamilton Rating Scale for Depression \[HAM-D-21\] \<=12 at the end of open label lead-in period entered stabilization period. OL Stabilization (12 weeks): Same dose as Day 92 in OL lead in period, on Day 120 once every 4 weeks. Participants who completed stabilization period and maintained stabilization criteria throughout 12 weeks entered double- bind (DB) relapse prevention period. DB Relapse prevention period (15 months): Same dose as Day 92 once every 4 weeks until one of the following occurred: met the prospectively defined relapse criteria; discontinued treatment for a reason other than relapse; withdrew consent; lost to follow-up; completed 15 months of double-blind treatment.
Placebo
Participants did not receive placebo during OL lead in period and OL stabilization period. Participants received matching placebo injections of 20 percent Intralipid (200 milligram per milliliter \[mg/mL\]) emulsion, once every 4 weeks during double-blind relapse prevention period.
Open-label Lead in Period
STARTED
667
0
Open-label Lead in Period
COMPLETED
432
0
Open-label Lead in Period
NOT COMPLETED
235
0
Open-label Stabilization Period
STARTED
432
0
Open-label Stabilization Period
COMPLETED
334
0
Open-label Stabilization Period
NOT COMPLETED
98
0
Double Blind Relapse Prevention Period
STARTED
164
170
Double Blind Relapse Prevention Period
COMPLETED
100
65
Double Blind Relapse Prevention Period
NOT COMPLETED
64
105

Reasons for withdrawal

Reasons for withdrawal
Measure
Paliperidone Palmitate
Open Label (OL) Lead-in (13 weeks): 234 milligram (mg) injection on Day 1, 156 mg on Day 8, flexible dose between 78-234 mg on Days 36, 64, and 92. Participants who met criteria: Positive and Negative Syndrome Scale (PANSS) total score less than or equal to (\<=) 70, and Young Mania Rating Scale \[YMRS\] and Hamilton Rating Scale for Depression \[HAM-D-21\] \<=12 at the end of open label lead-in period entered stabilization period. OL Stabilization (12 weeks): Same dose as Day 92 in OL lead in period, on Day 120 once every 4 weeks. Participants who completed stabilization period and maintained stabilization criteria throughout 12 weeks entered double- bind (DB) relapse prevention period. DB Relapse prevention period (15 months): Same dose as Day 92 once every 4 weeks until one of the following occurred: met the prospectively defined relapse criteria; discontinued treatment for a reason other than relapse; withdrew consent; lost to follow-up; completed 15 months of double-blind treatment.
Placebo
Participants did not receive placebo during OL lead in period and OL stabilization period. Participants received matching placebo injections of 20 percent Intralipid (200 milligram per milliliter \[mg/mL\]) emulsion, once every 4 weeks during double-blind relapse prevention period.
Open-label Lead in Period
Lost to Follow-up
32
0
Open-label Lead in Period
Pregnancy
1
0
Open-label Lead in Period
Withdrawal by Subject
69
0
Open-label Lead in Period
> 6 Weeks Between 2 Study Drug
4
0
Open-label Lead in Period
Other
14
0
Open-label Lead in Period
Subject Failed Stabilization Criteria
47
0
Open-label Lead in Period
Adverse Event
41
0
Open-label Lead in Period
Death
1
0
Open-label Lead in Period
Lack of Efficacy
26
0
Open-label Stabilization Period
Adverse Event
9
0
Open-label Stabilization Period
Death
2
0
Open-label Stabilization Period
Lost to Follow-up
10
0
Open-label Stabilization Period
Lack of Efficacy
5
0
Open-label Stabilization Period
Withdrawal by Subject
29
0
Open-label Stabilization Period
Subject Failed Stabilization Criteria
35
0
Open-label Stabilization Period
Other
8
0
Double Blind Relapse Prevention Period
Other
2
3
Double Blind Relapse Prevention Period
Adverse Event
12
3
Double Blind Relapse Prevention Period
Death
2
0
Double Blind Relapse Prevention Period
Lost to Follow-up
2
9
Double Blind Relapse Prevention Period
Pregnancy
1
0
Double Blind Relapse Prevention Period
Withdrawal by Subject
19
30
Double Blind Relapse Prevention Period
Experienced Relapse
25
57
Double Blind Relapse Prevention Period
> 6 Weeks Between 2 Study Drug
1
3

Baseline Characteristics

A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Entire Study Population
n=667 Participants
Included all participants who received at least 1 dose of paliperidone palmitate in open-label lead in period.
Age, Continuous
39.5 years
STANDARD_DEVIATION 10.70 • n=99 Participants
Sex: Female, Male
Female
310 Participants
n=99 Participants
Sex: Female, Male
Male
357 Participants
n=99 Participants

PRIMARY outcome

Timeframe: Day 1 up to Month 15 of double blind relapse prevention period

Population: Double-blind(DB) Intent-to-Treat(ITT) analysis set included all randomly assigned participants who received at least 1 injection of DB study medication.'n' signifies participants who were evaluable for each specified category,for each arm.

Relapse was defined as first occurrence of any 1 of following:psychiatric hospitalization due to worsening symptoms; any intervention employed to avert imminent hospitalization due to worsening symptoms or need for additional antipsychotic,antidepressants/mood stabilizing medication; deliberate self-injury,suicidal/homicidal ideation that is clinically significant as determined by investigator,or violent behavior resulting in clinically significant injury to another person or property damage; worsening of any 1 or more of 8 selected positive and negative syndrome scale(PANSS) items to a score of greater than or equal to (\>= 6) after randomization(if the score for the corresponding item was less than or equal to \[\<=\] 4 at randomization); worsening of certain other measures in specific ways at 2 consecutive visits. Relapse by subgroup of participants on monotherapy,adjunctive therapy to antidepressants/mood stabilizers,participants with psychotic symptoms/mood symptoms was examined.

Outcome measures

Outcome measures
Measure
Paliperidone Palmitate
n=164 Participants
DB Relapse prevention period (15 months): Same dose as Day 92, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants, until one of the following occurred: met the prospectively defined relapse criteria; discontinued treatment for a reason other than relapse; withdrew consent; lost to follow-up; completed 15 months of double-blind treatment.
Placebo
n=170 Participants
Matching placebo injections of 20 percent Intralipid (200 milligram per milliliter \[mg/mL\]) emulsion, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants.
Double-blind: Percentage of Participants Who Experienced Relapse
All Participants (n=164, 170)
15.2 percentage of participants
33.5 percentage of participants
Double-blind: Percentage of Participants Who Experienced Relapse
Monotherapy subset (n=78, 73)
11.5 percentage of participants
32.9 percentage of participants
Double-blind: Percentage of Participants Who Experienced Relapse
Adjunct therapy subset (n=86, 97)
18.6 percentage of participants
34.0 percentage of participants
Double-blind: Percentage of Participants Who Experienced Relapse
Psychotic Symptoms (n=164, 170)
12.8 percentage of participants
31.2 percentage of participants
Double-blind: Percentage of Participants Who Experienced Relapse
Mood Symptoms;Any Mood Symptoms (n=164, 170)
11.0 percentage of participants
28.2 percentage of participants
Double-blind: Percentage of Participants Who Experienced Relapse
Mood Symptoms;Manic (n=164, 170)
3.0 percentage of participants
9.4 percentage of participants
Double-blind: Percentage of Participants Who Experienced Relapse
Mood Symptoms;Depressive (n=164, 170)
4.9 percentage of participants
13.5 percentage of participants
Double-blind: Percentage of Participants Who Experienced Relapse
Mood Symptoms; Mixed (n=164, 170)
3.0 percentage of participants
5.3 percentage of participants

SECONDARY outcome

Timeframe: Baseline and Week 64 of double blind relapse prevention period

Population: DB ITT analysis set which included all randomly assigned participants who received at least one injection of double-blind study medication. 'n' signifies participants who were evaluable at each specified time point for each arm, respectively.

The PSP scale was designed to assess the degree of dysfunction a participant exhibits during a month prior to any visit within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior, each rated on 6-point scale (1=absent to 6=very severe). Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning. A score lying between 71 and 100 indicated a good functioning; one between 31 and 70 indicated varying degrees of difficulty, and a score of \<=30 indicated functioning so poor that participant required intensive supervision.

Outcome measures

Outcome measures
Measure
Paliperidone Palmitate
n=164 Participants
DB Relapse prevention period (15 months): Same dose as Day 92, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants, until one of the following occurred: met the prospectively defined relapse criteria; discontinued treatment for a reason other than relapse; withdrew consent; lost to follow-up; completed 15 months of double-blind treatment.
Placebo
n=170 Participants
Matching placebo injections of 20 percent Intralipid (200 milligram per milliliter \[mg/mL\]) emulsion, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants.
Double-blind: Change From Baseline in Personal and Social Performance (PSP) Total Score at Week 64 (Total Mixed Model Repeated Measures [MMRM] Analysis of Covariance [ANCOVA])
Baseline (n=164, 170)
72.8 Units on a scale
Standard Error 0.81
74.5 Units on a scale
Standard Error 0.81
Double-blind: Change From Baseline in Personal and Social Performance (PSP) Total Score at Week 64 (Total Mixed Model Repeated Measures [MMRM] Analysis of Covariance [ANCOVA])
Change at Week 64 (n=98, 65)
2.0 Units on a scale
Standard Error 0.92
-1.3 Units on a scale
Standard Error 1.03

SECONDARY outcome

Timeframe: Baseline and Endpoint (Week 13/LOCF) in Open-label (OL) Lead-in period, Endpoint (Week 25/LOCF) in open-label stabilization period

Population: OL ITT analysis set which included all randomly assigned participants who received at least one injection of open-label study medication. Last Observation Carried Forward (LOCF) method was used to impute missing values. 'n' signifies participants who were evaluable at each specified time point.

The PSP scale was designed to assess the degree of dysfunction a participant exhibits during a month prior to any visit within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior, each rated on 6-point scale (1=absent to 6=very severe). Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning. A score lying between 71 and 100 indicated a good functioning; one between 31 and 70 indicated varying degrees of difficulty, and a score of \<=30 indicated functioning so poor that participant required intensive supervision.

Outcome measures

Outcome measures
Measure
Paliperidone Palmitate
n=667 Participants
DB Relapse prevention period (15 months): Same dose as Day 92, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants, until one of the following occurred: met the prospectively defined relapse criteria; discontinued treatment for a reason other than relapse; withdrew consent; lost to follow-up; completed 15 months of double-blind treatment.
Placebo
Matching placebo injections of 20 percent Intralipid (200 milligram per milliliter \[mg/mL\]) emulsion, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants.
Open-label: Change From Baseline in Personal and Social Performance (PSP) Total Score at Endpoint
OL Lead-in Period:Baseline (n=667)
51.4 Units on a Scale
Standard Deviation 11.02
Open-label: Change From Baseline in Personal and Social Performance (PSP) Total Score at Endpoint
OL Lead-in Period:Change at Endpoint (n=622)
12.6 Units on a Scale
Standard Deviation 13.71
Open-label: Change From Baseline in Personal and Social Performance (PSP) Total Score at Endpoint
OL Stabilization Period:Change at Endpoint (n=622)
13.8 Units on a Scale
Standard Deviation 14.92

SECONDARY outcome

Timeframe: Baseline and Endpoint (Week 64/LOCF) in double-blind period

Population: DB ITT analysis set which included all randomly assigned participants who received at least one injection of double-blind study medication. LOCF method was used to impute missing values. 'n' signifies participants who were evaluable at each specified time point for each arm, respectively.

The PSP scale was designed to assess the degree of dysfunction a participant exhibits during a month prior to any visit within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior, each rated on 6-point scale (1=absent to 6=very severe). Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning. A score lying between 71 and 100 indicated a good functioning; one between 31 and 70 indicated varying degrees of difficulty, and a score of \<=30 indicated functioning so poor that participant required intensive supervision.

Outcome measures

Outcome measures
Measure
Paliperidone Palmitate
n=164 Participants
DB Relapse prevention period (15 months): Same dose as Day 92, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants, until one of the following occurred: met the prospectively defined relapse criteria; discontinued treatment for a reason other than relapse; withdrew consent; lost to follow-up; completed 15 months of double-blind treatment.
Placebo
n=170 Participants
Matching placebo injections of 20 percent Intralipid (200 milligram per milliliter \[mg/mL\]) emulsion, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants.
Double-blind: Change From Baseline in Personal and Social Performance (PSP) Total Score at Endpoint
Double-blind: Baseline (n=164, 170)
74.5 Units on a Scale
Standard Error 0.81
72.8 Units on a Scale
Standard Error 0.81
Double-blind: Change From Baseline in Personal and Social Performance (PSP) Total Score at Endpoint
Double-blind: Change at Endpoint (n=161,168)
0.5 Units on a Scale
Standard Error 1.15
-4.1 Units on a Scale
Standard Error 1.13

SECONDARY outcome

Timeframe: Baseline and Endpoint (Week 64/LOCF) in DB period

Population: DB ITT analysis set which included all randomly assigned participants who received at least one injection of double-blind study medication. LOCF method was used to impute missing values.'n' signifies participants who were evaluable at each specified time point for each arm, respectively.

The PSP scale was designed to assess the degree of dysfunction a participant exhibits during a month prior to any visit within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior, each rated on 6-point scale (1=absent to 6=very severe). Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning. Number of participants in each specific category; good functioning (PSP total score \>70), variable functioning (PSP total score between 31 and 70), and poor functioning (PSP total score \<=30) were assessed.

Outcome measures

Outcome measures
Measure
Paliperidone Palmitate
n=164 Participants
DB Relapse prevention period (15 months): Same dose as Day 92, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants, until one of the following occurred: met the prospectively defined relapse criteria; discontinued treatment for a reason other than relapse; withdrew consent; lost to follow-up; completed 15 months of double-blind treatment.
Placebo
n=170 Participants
Matching placebo injections of 20 percent Intralipid (200 milligram per milliliter \[mg/mL\]) emulsion, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants.
Double-blind: Number of Participants With Personal and Social Performance (PSP) Categorical Scores
Baseline: Poor (n=164, 170)
0 participants
0 participants
Double-blind: Number of Participants With Personal and Social Performance (PSP) Categorical Scores
Baseline: Variable (n=164, 170)
69 participants
84 participants
Double-blind: Number of Participants With Personal and Social Performance (PSP) Categorical Scores
Baseline: Good (n=164, 170)
95 participants
86 participants
Double-blind: Number of Participants With Personal and Social Performance (PSP) Categorical Scores
Endpoint: Poor (n=161, 168)
1 participants
4 participants
Double-blind: Number of Participants With Personal and Social Performance (PSP) Categorical Scores
Endpoint: Variable (n=161, 168)
65 participants
95 participants
Double-blind: Number of Participants With Personal and Social Performance (PSP) Categorical Scores
Endpoint: Good (n=161, 168)
95 participants
69 participants

SECONDARY outcome

Timeframe: Baseline and Endpoint (Week 13/LOCF) in OL Lead-in period, Endpoint (Week 25/LOCF) in open-label stabilization period

Population: OL ITT analysis set which included all randomly assigned participants who received at least one injection of open-label study medication. LOCF method was used to impute missing values. 'n' signifies participants who were evaluable at each specified time point.

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

Outcome measures

Outcome measures
Measure
Paliperidone Palmitate
n=667 Participants
DB Relapse prevention period (15 months): Same dose as Day 92, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants, until one of the following occurred: met the prospectively defined relapse criteria; discontinued treatment for a reason other than relapse; withdrew consent; lost to follow-up; completed 15 months of double-blind treatment.
Placebo
Matching placebo injections of 20 percent Intralipid (200 milligram per milliliter \[mg/mL\]) emulsion, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants.
Open-label: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Endpoint
OL Lead-in Period:Baseline (n=667)
85.8 Units on a scale
Standard Deviation 12.76
Open-label: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Endpoint
OL Lead-in Period:Change at Endpoint (n=653)
-21.8 Units on a scale
Standard Deviation 16.39
Open-label: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Endpoint
OL Stabilization Period:Change at Endpoint (n=653)
-23.8 Units on a scale
Standard Deviation 18.30

SECONDARY outcome

Timeframe: Baseline and Endpoint (Week 64/LOCF) in double-blind period

Population: DB ITT analysis set which included all randomly assigned participants who received at least one injection of double-blind study medication. LOCF method was used to impute missing values. 'n' signifies participants who were evaluable at each specified time point for each arm, respectively.

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

Outcome measures

Outcome measures
Measure
Paliperidone Palmitate
n=164 Participants
DB Relapse prevention period (15 months): Same dose as Day 92, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants, until one of the following occurred: met the prospectively defined relapse criteria; discontinued treatment for a reason other than relapse; withdrew consent; lost to follow-up; completed 15 months of double-blind treatment.
Placebo
n=170 Participants
Matching placebo injections of 20 percent Intralipid (200 milligram per milliliter \[mg/mL\]) emulsion, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants.
Double-blind: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Endpoint
Double-blind: Baseline (n=164, 170)
51.1 Units on a scale
Standard Deviation 9.50
51.8 Units on a scale
Standard Deviation 9.47
Double-blind: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Endpoint
Double-blind: Change at Endpoint (n=161, 168)
0.5 Units on a scale
Standard Deviation 14.01
7.4 Units on a scale
Standard Deviation 18.53

SECONDARY outcome

Timeframe: Baseline and Endpoint (Week 13/LOCF) in OL Lead-in period, Endpoint (Week 25/LOCF) in open-label stabilization period

Population: OL ITT analysis set which included all randomly assigned participants who received at least one injection of open-label study medication. LOCF method was used to impute missing values. n' signifies participants who were evaluable at each specified time point.

The HAM-D-21 is a 21-item, clinician-rated scale to evaluate depressed mood as well as the vegetative and cognitive symptoms of depression. The items are rated on a 5-point (0 to 4) scale. The 5-point scale items use a rating of 0 (absent), 1 (doubtful to mild), 2 (mild to moderate), 3 (moderate to severe), and 4 (very severe). A rating of 4 is usually reserved for extreme symptoms. The responses for all 21 items are summed to yield the HAM-D-21 total score that ranges from 0-63.

Outcome measures

Outcome measures
Measure
Paliperidone Palmitate
n=667 Participants
DB Relapse prevention period (15 months): Same dose as Day 92, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants, until one of the following occurred: met the prospectively defined relapse criteria; discontinued treatment for a reason other than relapse; withdrew consent; lost to follow-up; completed 15 months of double-blind treatment.
Placebo
Matching placebo injections of 20 percent Intralipid (200 milligram per milliliter \[mg/mL\]) emulsion, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants.
Open-label: Change From Baseline in Hamilton Rating Scale for Depression (HAM-D-21) Total Score at Endpoint
OL Lead-in Period:Baseline (n=667)
20.4 Units on a scale
Standard Deviation 7.81
Open-label: Change From Baseline in Hamilton Rating Scale for Depression (HAM-D-21) Total Score at Endpoint
OL Lead-in Period:Change at Endpoint (n=653)
-9.7 Units on a scale
Standard Deviation 8.53
Open-label: Change From Baseline in Hamilton Rating Scale for Depression (HAM-D-21) Total Score at Endpoint
OL Stabilization Period:Change at Endpoint (n=653)
-9.9 Units on a scale
Standard Deviation 9.08

SECONDARY outcome

Timeframe: Baseline and Endpoint (Week 64/LOCF) in double-blind period

Population: DB ITT analysis set which included all randomly assigned participants who received at least one injection of double-blind study medication. LOCF method was used to impute missing values. 'n' signifies participants who were evaluable at each specified time point for each arm, respectively.

The HAM-D-21 is a 21-item, clinician-rated scale to evaluate depressed mood as well as the vegetative and cognitive symptoms of depression. The items are rated on a 5-point (0 to 4) scale. The 5-point scale items use a rating of 0 (absent), 1 (doubtful to mild), 2 (mild to moderate), 3 (moderate to severe), and 4 (very severe). A rating of 4 is usually reserved for extreme symptoms. The responses for all 21 items are summed to yield the HAM-D-21 total score that ranges from 0-63.

Outcome measures

Outcome measures
Measure
Paliperidone Palmitate
n=164 Participants
DB Relapse prevention period (15 months): Same dose as Day 92, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants, until one of the following occurred: met the prospectively defined relapse criteria; discontinued treatment for a reason other than relapse; withdrew consent; lost to follow-up; completed 15 months of double-blind treatment.
Placebo
n=170 Participants
Matching placebo injections of 20 percent Intralipid (200 milligram per milliliter \[mg/mL\]) emulsion, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants.
Double-blind: Change From Baseline in Hamilton Rating Scale for Depression (HAM-D-21) Total Score at Endpoint
Double-blind: Baseline (n=164, 170)
5.7 Units on a scale
Standard Deviation 3.24
5.6 Units on a scale
Standard Deviation 3.32
Double-blind: Change From Baseline in Hamilton Rating Scale for Depression (HAM-D-21) Total Score at Endpoint
Double-blind: Change at Endpoint (n=161, 168)
0.8 Units on a scale
Standard Deviation 5.40
3.4 Units on a scale
Standard Deviation 7.42

SECONDARY outcome

Timeframe: Baseline and Endpoint (Week 13/LOCF) in OL Lead-in period, Endpoint (Week 25/LOCF) in open-label stabilization period

Population: OL ITT analysis set which included all randomly assigned participants who received at least one injection of open-label study medication. LOCF method was used to impute missing values. 'n' signifies participants who were evaluable at each specified time point.

The YMRS was designed to measure the severity of manic symptoms, to gauge the effect of treatment on mania severity, and to detect a return of manic symptoms (for example relapse or recurrence). YMRS is a checklist of 11 items that are ranked on a scale of 0 to 4 or 0 to 8. Seven of the items (elevated mood, increased motor activity, sexual interest, sleep, language-thought disorder, appearance, and insight) are ranked 0 to 4 and have descriptors associated with each severity level (that is, 0, 1, 2, 3, 4). Four of the items (irritability, speech, content, and disruptive-aggressive behavior) are scored 0 to 8 and have descriptors for every other increment (that is, 0, 2, 4, 6, 8). The item score is based on participant's report of his or her condition and clinician's behavioral observations during the interview, with emphasis on the latter. Higher scores indicate worsening. Responses are summed to yield YMRS total score ranging from 0 to 60.

Outcome measures

Outcome measures
Measure
Paliperidone Palmitate
n=667 Participants
DB Relapse prevention period (15 months): Same dose as Day 92, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants, until one of the following occurred: met the prospectively defined relapse criteria; discontinued treatment for a reason other than relapse; withdrew consent; lost to follow-up; completed 15 months of double-blind treatment.
Placebo
Matching placebo injections of 20 percent Intralipid (200 milligram per milliliter \[mg/mL\]) emulsion, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants.
Open-label: Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Endpoint
OL Lead-in Period:Baseline (n=667)
18.6 Units on a scale
Standard Deviation 9.48
Open-label: Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Endpoint
OL Lead-in Period:Change at Endpoint (n=653)
-9.9 Units on a scale
Standard Deviation 9.45
Open-label: Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Endpoint
OL Stabilization Period:Change at Endpoint (n=653)
-10.5 Units on a scale
Standard Deviation 10.14

SECONDARY outcome

Timeframe: Baseline and Endpoint (Week 64/LOCF) in double-blind period

Population: DB ITT analysis set which included all randomly assigned participants who received at least one injection of double-blind study medication. LOCF method was used to impute missing values. 'n' signifies participants who were evaluable at each specified time point for each arm, respectively.

The YMRS was designed to measure the severity of manic symptoms, to gauge the effect of treatment on mania severity, and to detect a return of manic symptoms (for example relapse or recurrence). YMRS is a checklist of 11 items that are ranked on a scale of 0 to 4 or 0 to 8. Seven of the items (elevated mood, increased motor activity, sexual interest, sleep, language-thought disorder, appearance, and insight) are ranked 0 to 4 and have descriptors associated with each severity level (that is, 0, 1, 2, 3, 4). Four of the items (irritability, speech, content, and disruptive-aggressive behavior) are scored 0 to 8 and have descriptors for every other increment (that is, 0, 2, 4, 6, 8). The item score is based on participant's report of his or her condition and clinician's behavioral observations during the interview, with emphasis on the latter. Higher scores indicate worsening. Responses are summed to yield YMRS total score ranging from 0 to 60.

Outcome measures

Outcome measures
Measure
Paliperidone Palmitate
n=164 Participants
DB Relapse prevention period (15 months): Same dose as Day 92, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants, until one of the following occurred: met the prospectively defined relapse criteria; discontinued treatment for a reason other than relapse; withdrew consent; lost to follow-up; completed 15 months of double-blind treatment.
Placebo
n=170 Participants
Matching placebo injections of 20 percent Intralipid (200 milligram per milliliter \[mg/mL\]) emulsion, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants.
Double-blind: Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Endpoint
Double-blind: Baseline (n=164, 170)
4.4 Units on a scale
Standard Deviation 3.46
4.4 Units on a scale
Standard Deviation 3.40
Double-blind: Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Endpoint
Double-blind: Change at Endpoint (n=161,168)
-0.1 Units on a scale
Standard Deviation 5.47
3.2 Units on a scale
Standard Deviation 7.21

SECONDARY outcome

Timeframe: Baseline and Endpoint (Week 13/LOCF) in OL Lead-in period, Endpoint (Week 25/LOCF) in open-label stabilization period

Population: OL ITT analysis set which included all randomly assigned participants who received at least one injection of open-label study medication. LOCF method was used to impute missing values. 'n' signifies participants who were evaluable at each specified time point.

The CGI-S-SCA is a syndrome-specific 7-point scale (from 1 indicating not ill to 7 indicating very severely ill) that includes an overall severity score as well as scores for the positive, negative, manic, and depressive domains of the illness. The CGI-S-SCA was used to assess the level of overall impairment, as well as that related to each domain, at the time of the visit and for the week prior to the visit".

Outcome measures

Outcome measures
Measure
Paliperidone Palmitate
n=667 Participants
DB Relapse prevention period (15 months): Same dose as Day 92, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants, until one of the following occurred: met the prospectively defined relapse criteria; discontinued treatment for a reason other than relapse; withdrew consent; lost to follow-up; completed 15 months of double-blind treatment.
Placebo
Matching placebo injections of 20 percent Intralipid (200 milligram per milliliter \[mg/mL\]) emulsion, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants.
Open-label: Change From Baseline in Clinical Global Impression - Severity Schizoaffective Scale (CGI-S-SCA) Overall Score at Endpoint
OL Lead-in Period:Baseline (n=667)
4.4 Units on a scale
Standard Deviation 0.58
Open-label: Change From Baseline in Clinical Global Impression - Severity Schizoaffective Scale (CGI-S-SCA) Overall Score at Endpoint
OL Lead-in Period:Change at Endpoint (n=652)
-1.3 Units on a scale
Standard Deviation 0.99
Open-label: Change From Baseline in Clinical Global Impression - Severity Schizoaffective Scale (CGI-S-SCA) Overall Score at Endpoint
OL Stabilization Period:Change at Endpoint (n=652)
-1.3 Units on a scale
Standard Deviation 1.07

SECONDARY outcome

Timeframe: Baseline and Endpoint (Week 64/LOCF) in double-blind period

Population: DB ITT analysis set which included all randomly assigned participants who received at least one injection of double-blind study medication. LOCF method was used to impute missing values. 'n' signifies participants who were evaluable at each specified time point for each arm, respectively.

The CGI-S-SCA is a syndrome-specific 7-point scale (from 1 indicating not ill to 7 indicating very severely ill) that includes an overall severity score as well as scores for the positive, negative, manic, and depressive domains of the illness. The CGI-S-SCA was used to assess the level of overall impairment, as well as that related to each domain, at the time of the visit and for the week prior to the visit".

Outcome measures

Outcome measures
Measure
Paliperidone Palmitate
n=164 Participants
DB Relapse prevention period (15 months): Same dose as Day 92, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants, until one of the following occurred: met the prospectively defined relapse criteria; discontinued treatment for a reason other than relapse; withdrew consent; lost to follow-up; completed 15 months of double-blind treatment.
Placebo
n=170 Participants
Matching placebo injections of 20 percent Intralipid (200 milligram per milliliter \[mg/mL\]) emulsion, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants.
Double-blind: Change From Baseline in Clinical Global Impression - Severity Schizoaffective Scale (CGI-S-SCA) Overall Score at Endpoint
Double-blind: Baseline (n=164, 170)
2.4 Units on a scale
Standard Deviation 0.68
2.5 Units on a scale
Standard Deviation 0.69
Double-blind: Change From Baseline in Clinical Global Impression - Severity Schizoaffective Scale (CGI-S-SCA) Overall Score at Endpoint
Double-blind: Change at Endpoint (n=161,168)
0.0 Units on a scale
Standard Deviation 1.02
0.4 Units on a scale
Standard Deviation 1.15

Adverse Events

Open Label - Paliperidone Palmitate

Serious events: 54 serious events
Other events: 332 other events
Deaths: 0 deaths

Double Blind - Paliperidone Palmitate

Serious events: 9 serious events
Other events: 79 other events
Deaths: 0 deaths

Double Blind - Placebo

Serious events: 16 serious events
Other events: 62 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Open Label - Paliperidone Palmitate
n=667 participants at risk
Open Label (OL) Lead-in (13 weeks): 234 milligram (mg) injection on Day 1, 156 mg on Day 8, flexible dose between 78-234 mg on Days 36, 64, and 92, given as monotherapy and as an adjunct to mood stabilizers or antidepressants. Participants who met criteria: Positive and Negative Syndrome Scale (PANSS) total score less than or equal to (\<=) 70, and Young Mania Rating Scale \[YMRS\] and Hamilton Rating Scale for Depression \[HAM-D-21\] \<=12 at the end of open label lead-in period entered stabilization period. OL Stabilization (12 weeks): Same dose as Day 92 in OL lead in period, on Day 120 once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants. Participants who completed stabilization period and maintained stabilization criteria throughout 12 weeks entered double- bind (DB) relapse prevention period.
Double Blind - Paliperidone Palmitate
n=164 participants at risk
DB Relapse prevention period (15 months): Same dose as Day 92, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants, until one of the following occurred: met the prospectively defined relapse criteria; discontinued treatment for a reason other than relapse; withdrew consent; lost to follow-up; completed 15 months of double-blind treatment.
Double Blind - Placebo
n=170 participants at risk
Participants did not receive placebo during OL lead in period and OL stabilization period. Participants received matching placebo injections of 20 percent Intralipid (200 milligram per milliliter \[mg/mL\]) emulsion, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants during DB relapse prevention period.
Cardiac disorders
Atrioventricular Block Complete
0.15%
1/667
0.00%
0/164
0.00%
0/170
Cardiac disorders
Cardiac Failure Congestive
0.00%
0/667
0.61%
1/164
0.00%
0/170
Cardiac disorders
Cardiogenic Shock
0.15%
1/667
0.00%
0/164
0.00%
0/170
Cardiac disorders
Congestive Cardiomyopathy
0.00%
0/667
0.61%
1/164
0.00%
0/170
Cardiac disorders
Coronary Artery Disease
0.00%
0/667
0.61%
1/164
0.00%
0/170
Cardiac disorders
Myocardial Infarction
0.15%
1/667
0.00%
0/164
0.00%
0/170
Ear and labyrinth disorders
Meniere's Disease
0.00%
0/667
0.00%
0/164
0.59%
1/170
Gastrointestinal disorders
Colitis
0.15%
1/667
0.00%
0/164
0.00%
0/170
Gastrointestinal disorders
Gastrooesophageal Reflux Disease
0.00%
0/667
0.61%
1/164
0.00%
0/170
Gastrointestinal disorders
Vomiting
0.15%
1/667
0.00%
0/164
0.00%
0/170
General disorders
Chest Pain
0.00%
0/667
0.61%
1/164
0.00%
0/170
General disorders
Hyperthermia
0.15%
1/667
0.00%
0/164
0.00%
0/170
Hepatobiliary disorders
Cholelithiasis
0.15%
1/667
0.00%
0/164
0.00%
0/170
Infections and infestations
Bronchitis
0.00%
0/667
0.61%
1/164
0.00%
0/170
Infections and infestations
Diverticulitis
0.15%
1/667
0.00%
0/164
0.00%
0/170
Infections and infestations
Lobar Pneumonia
0.15%
1/667
0.00%
0/164
0.00%
0/170
Injury, poisoning and procedural complications
Brain Contusion
0.00%
0/667
0.00%
0/164
0.59%
1/170
Injury, poisoning and procedural complications
Multiple Injuries
0.15%
1/667
0.00%
0/164
0.00%
0/170
Injury, poisoning and procedural complications
Overdose
0.00%
0/667
0.61%
1/164
0.00%
0/170
Injury, poisoning and procedural complications
Road Traffic Accident
0.00%
0/667
0.00%
0/164
0.59%
1/170
Nervous system disorders
Coma
0.15%
1/667
0.00%
0/164
0.00%
0/170
Nervous system disorders
Viith Nerve Paralysis
0.00%
0/667
0.00%
0/164
0.59%
1/170
Psychiatric disorders
Completed Suicide
0.15%
1/667
0.00%
0/164
0.00%
0/170
Psychiatric disorders
Confusional State
0.15%
1/667
0.00%
0/164
0.00%
0/170
Psychiatric disorders
Delusion
0.00%
0/667
0.00%
0/164
0.59%
1/170
Psychiatric disorders
Depression
0.15%
1/667
1.2%
2/164
0.00%
0/170
Psychiatric disorders
Depression Suicidal
0.15%
1/667
0.00%
0/164
0.00%
0/170
Psychiatric disorders
Depressive Symptom
0.30%
2/667
0.00%
0/164
0.00%
0/170
Psychiatric disorders
Hallucination, Auditory
0.15%
1/667
0.00%
0/164
0.00%
0/170
Psychiatric disorders
Homicidal Ideation
0.15%
1/667
0.00%
0/164
0.00%
0/170
Psychiatric disorders
Mania
0.45%
3/667
0.00%
0/164
0.59%
1/170
Psychiatric disorders
Paranoia
0.15%
1/667
0.00%
0/164
0.00%
0/170
Psychiatric disorders
Psychotic Disorder
0.60%
4/667
1.2%
2/164
1.2%
2/170
Psychiatric disorders
Restlessness
0.15%
1/667
0.00%
0/164
0.00%
0/170
Psychiatric disorders
Schizoaffective Disorder
2.4%
16/667
0.61%
1/164
4.1%
7/170
Psychiatric disorders
Suicidal Ideation
2.2%
15/667
0.00%
0/164
1.2%
2/170
Psychiatric disorders
Suicide Attempt
0.30%
2/667
0.00%
0/164
0.00%
0/170
Renal and urinary disorders
Bladder Prolapse
0.15%
1/667
0.00%
0/164
0.00%
0/170
Surgical and medical procedures
Therapy Regimen Changed
0.15%
1/667
0.00%
0/164
0.00%
0/170
Vascular disorders
Deep Vein Thrombosis
0.30%
2/667
0.00%
0/164
0.00%
0/170

Other adverse events

Other adverse events
Measure
Open Label - Paliperidone Palmitate
n=667 participants at risk
Open Label (OL) Lead-in (13 weeks): 234 milligram (mg) injection on Day 1, 156 mg on Day 8, flexible dose between 78-234 mg on Days 36, 64, and 92, given as monotherapy and as an adjunct to mood stabilizers or antidepressants. Participants who met criteria: Positive and Negative Syndrome Scale (PANSS) total score less than or equal to (\<=) 70, and Young Mania Rating Scale \[YMRS\] and Hamilton Rating Scale for Depression \[HAM-D-21\] \<=12 at the end of open label lead-in period entered stabilization period. OL Stabilization (12 weeks): Same dose as Day 92 in OL lead in period, on Day 120 once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants. Participants who completed stabilization period and maintained stabilization criteria throughout 12 weeks entered double- bind (DB) relapse prevention period.
Double Blind - Paliperidone Palmitate
n=164 participants at risk
DB Relapse prevention period (15 months): Same dose as Day 92, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants, until one of the following occurred: met the prospectively defined relapse criteria; discontinued treatment for a reason other than relapse; withdrew consent; lost to follow-up; completed 15 months of double-blind treatment.
Double Blind - Placebo
n=170 participants at risk
Participants did not receive placebo during OL lead in period and OL stabilization period. Participants received matching placebo injections of 20 percent Intralipid (200 milligram per milliliter \[mg/mL\]) emulsion, once every 4 weeks, given as monotherapy and as an adjunct to mood stabilizers or antidepressants during DB relapse prevention period.
Gastrointestinal disorders
Dry Mouth
2.2%
15/667
0.00%
0/164
0.59%
1/170
Gastrointestinal disorders
Constipation
2.1%
14/667
1.2%
2/164
0.00%
0/170
Gastrointestinal disorders
Diarrhoea
3.0%
20/667
2.4%
4/164
1.2%
2/170
Endocrine disorders
Hyperprolactinaemia
1.3%
9/667
4.3%
7/164
1.2%
2/170
Gastrointestinal disorders
Nausea
2.5%
17/667
1.2%
2/164
1.8%
3/170
Gastrointestinal disorders
Toothache
1.2%
8/667
3.0%
5/164
1.2%
2/170
General disorders
Fatigue
3.0%
20/667
1.8%
3/164
0.00%
0/170
General disorders
Injection Site Pain
10.6%
71/667
0.61%
1/164
1.2%
2/170
General disorders
Pyrexia
1.2%
8/667
3.7%
6/164
1.2%
2/170
Infections and infestations
Nasopharyngitis
1.3%
9/667
5.5%
9/164
3.5%
6/170
Infections and infestations
Upper Respiratory Tract Infection
2.1%
14/667
4.3%
7/164
2.4%
4/170
Infections and infestations
Urinary Tract Infection
1.2%
8/667
3.0%
5/164
2.4%
4/170
Investigations
Blood Prolactin Increased
0.60%
4/667
2.4%
4/164
1.2%
2/170
Investigations
Glycosylated Haemoglobin Increased
0.15%
1/667
1.2%
2/164
2.4%
4/170
Investigations
Weight Decreased
0.30%
2/667
3.0%
5/164
1.2%
2/170
Investigations
Weight Increased
8.5%
57/667
8.5%
14/164
4.7%
8/170
Metabolism and nutrition disorders
Increased Appetite
2.7%
18/667
0.00%
0/164
0.00%
0/170
Musculoskeletal and connective tissue disorders
Arthralgia
2.1%
14/667
1.2%
2/164
1.8%
3/170
Nervous system disorders
Akathisia
11.1%
74/667
3.0%
5/164
1.8%
3/170
Nervous system disorders
Dyskinesia
2.1%
14/667
0.61%
1/164
1.8%
3/170
Nervous system disorders
Headache
5.4%
36/667
5.5%
9/164
3.5%
6/170
Nervous system disorders
Parkinsonism
6.4%
43/667
1.8%
3/164
1.8%
3/170
Nervous system disorders
Somnolence
3.1%
21/667
1.2%
2/164
1.2%
2/170
Nervous system disorders
Tremor
3.4%
23/667
1.2%
2/164
2.4%
4/170
Psychiatric disorders
Anxiety
1.3%
9/667
1.8%
3/164
2.4%
4/170
Psychiatric disorders
Insomnia
10.0%
67/667
4.9%
8/164
7.1%
12/170
Psychiatric disorders
Schizoaffective Disorder
0.90%
6/667
2.4%
4/164
1.8%
3/170
Psychiatric disorders
Suicidal Ideation
2.4%
16/667
3.0%
5/164
1.2%
2/170
Reproductive system and breast disorders
Amenorrhoea
2.7%
18/667
1.8%
3/164
1.2%
2/170
Respiratory, thoracic and mediastinal disorders
Cough
1.5%
10/667
3.0%
5/164
1.2%
2/170

Additional Information

Director of Clinical Development

Janssen Scientific Affairs, LLC, Titusville, NJ

Results disclosure agreements

  • Principal investigator is a sponsor employee At least 60 days prior to submitting a manuscript the Site shall provide to Sponsor a copy of all such manuscripts and materials,and allow Sponsor 60 days to review and comment on them. If Sponsor requests, the Site shall remove any Confidential Information prior to submitting the materials.The Site agrees that if Study is part of a multi-center study,any publication by the Institution of results of the Study conducted at the Site shall not be made before the first multi-center publication.
  • Publication restrictions are in place

Restriction type: OTHER